華潤醫藥(03320.HK)旗下東阿阿膠與新西蘭政府簽署戰略合作備忘錄
華潤醫藥(03320.HK)宣布,旗下東阿阿膠受邀出席由新西蘭政府主辦的「新西蘭政府與中國重點合作夥伴簽約儀式」,並與新西蘭鹿業局於6月18日在上海舉行的簽約儀式上正式簽署《合作備忘錄》。
華潤醫藥指,新西蘭作為全球鹿產業領先國家,擁有超過80萬頭赤鹿存欄量及完善的產業鏈體系,其鹿製品以純天然飼養和高標準可溯源著稱。
東阿阿膠作為集團中藥大健康板塊的重要成員,推出「皇家圍場1619」品牌,瞄準以鹿產業為代表的健康消費新賽道作出前瞻性部署。未來,東阿阿膠將與新西蘭政府及當地企業進行更加深入的合作,整合全球資源,圍繞鹿茸等鹿副產品深加工、國際貿易,以及鹿茸藥材國際准入等問題開展全面探索,提升鹿產品研發能力,共同拓展國際市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.